Drug Profile
Mobilised peripheral blood cells - Cellect Biotechnology
Alternative Names: ApoGraft™; Mobilised peripheral blood cells - Cellect Biotechnology; Mobilised peripheral blood product - Cellect BiotechnologyLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Cellect Biotechnology
- Developer Cellect Biotechnology; Hadassah Medical Organization; Washington University
- Class Cell therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Graft-versus-host disease
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Graft-versus-host-disease(Prevention) in USA (Parenteral)
- 19 Dec 2022 Washington University School of Medicine, in collaboration with Cellect Biotechnology terminated a phase I trial in Graft-versus-host disease (Prevention) in USA (Parenteral), due to they loose funding (NCT04006652)
- 16 Dec 2020 Phase-I clinical trials in Graft-versus-host disease (Prevention) in USA (Parenteral) (NCT04006652)